Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Fanwei Meng. (2019) A novel role of HIF-1α/PROX-1/LYVE-1 axis on tissue regeneration after renal ischaemia/reperfusion in mice. Archives of Physiology and Biochemistry 125:4, pages 321-331.
Read now
Read now
Jolanta Malyszko, Jacek S. Malyszko & Joanna Matuszkiewicz-Rowinska. (2019) Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Expert Opinion on Therapeutic Targets 23:5, pages 407-421.
Read now
Read now
Jolanta Malyszko & Jacek S. Malyszko. (2016) Emerging drugs for the treatment of kidney disease-induced anemia. Expert Opinion on Emerging Drugs 21:3, pages 315-330.
Read now
Read now
Tammie Bishop & Peter J Ratcliffe. (2014) Signaling hypoxia by hypoxia-inducible factor protein hydroxylases: a historical overview and future perspectives. Hypoxia 2, pages 197-213.
Read now
Read now
Angus M Sinclair. (2013) Erythropoiesis stimulating agents: approaches to modulate activity. Biologics: Targets and Therapy 7, pages 161-174.
Read now
Read now
Yoshiki Higashijima, Tetsuhiro Tanaka & Masaomi Nangaku. (2013) Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials. Expert Opinion on Drug Discovery 8:8, pages 965-976.
Read now
Read now
Sucharita Sen Banerjee, Mahesh Thirunavukkarasu, Muhammad Tipu Rishi, Juan A. Sanchez, Nilanjana Maulik & Gautam Maulik. (2012) HIF–prolyl hydroxylases and cardiovascular diseases. Toxicology Mechanisms and Methods 22:5, pages 347-358.
Read now
Read now
Articles from other publishers (58)
Hideaki Ishii, Mariko Shibuya, Kanichi Kusano, Yu Sone, Takahiro Kamiya, Ai Wakuno, Hideki Ito, Kenji Miyata, Fumio Sato, Taisuke Kuroda, Masayuki Yamada & Gary Ngai-Wa Leung. (2022) Pharmacokinetic Study of Vadadustat and High-Resolution Mass Spectrometric
Characterization of its Novel Metabolites in Equines for the Purpose of Doping
Control. Current Drug Metabolism 23:10, pages 850-865.
Crossref
Crossref
Harilal Patel, Nirav Modi, Jaimin Chaudhari, Prakash Patel, Poonam Giri, Hiren Patel, Vrajesh Pandya, Ranjit Desai & Mukul Jain. (2022) Nonclinical Pharmacokinetic Evaluation of Desidustat: a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. European Journal of Drug Metabolism and Pharmacokinetics 47:5, pages 725-740.
Crossref
Crossref
Xin Zheng, Xia Chen, Tao Liu, Ji Jiang, Xinge Cui, Qian Zhao & Pei Hu. (2022) Liquid chromatography-tandem mass spectrometry methods for quantification of roxadustat (FG-4592) in human plasma and urine and the applications in two clinical pharmacokinetic studies. Journal of Chromatography B 1203, pages 123274.
Crossref
Crossref
Hideaki Ishii, Mariko Shibuya, Yat‐Ming So, Jenny K. Y. Wong, Emmie N. M. Ho, Kanichi Kusano, Yu Sone, Takahiro Kamiya, Ai Wakuno, Hideki Ito, Kenji Miyata, Masayuki Yamada & Gary Ngai‐Wa Leung. (2022) Long‐term monitoring of IOX4 in horse hair and its longitudinal distribution with segmental analysis using liquid chromatography/electrospray ionization Q Exactive high‐resolution mass spectrometry for the purpose of doping control. Drug Testing and Analysis 14:7, pages 1244-1254.
Crossref
Crossref
Zhouliang Guo, Jiayu Zi, Yanfei Hao, Yuyin Li, Zhenxing Liu, Qing Zhao, Limin Hao & Aipo Diao. (2022) Production of functional recombinant prolyl hydroxylase-2 enzyme in insect cells for small molecule inhibitor screening studies. Protein Expression and Purification 194, pages 106073.
Crossref
Crossref
Yuanyuan Ma, Zhiyuan Zhou, Guo-Yuan Yang, Jing Ding & Xin Wang. (2022) The Effect of Erythropoietin and Its Derivatives on Ischemic Stroke Therapy: A Comprehensive Review. Frontiers in Pharmacology 13.
Crossref
Crossref
Hideaki Ishii, Mariko Shibuya, Yat‐Ming So, Jenny K. Y. Wong, Emmie N. M. Ho, Kanichi Kusano, Yu Sone, Takahiro Kamiya, Ai Wakuno, Hideki Ito, Kenji Miyata, Masayuki Yamada & Gary Ngai‐Wa Leung. (2021) Comprehensive metabolic study of IOX4 in equine urine and plasma using liquid chromatography/electrospray ionization Q Exactive high‐resolution mass spectrometer for the purpose of doping control. Drug Testing and Analysis 14:2, pages 233-251.
Crossref
Crossref
Mingsong Shi, Xin Zhou, Yao Cai, Penghui Li, Dengxue Qin, Xinrong Yan, Meng Du, Shuo Li & Dingguo Xu. (2021) Inhibition mechanism of hydroxyproline-like small inhibitors to disorder HIF-VHL interaction by molecular dynamic simulations and binding free energy calculations. Chinese Journal of Chemical Physics 34:6, pages 814-824.
Crossref
Crossref
Guodong Li, Chung-Nga Ko, Dan Li, Chao Yang, Wanhe Wang, Guan-Jun Yang, Carmelo Di Primo, Vincent Kam Wai Wong, Yaozu Xiang, Ligen Lin, Dik-Lung Ma & Chung-Hang Leung. (2021) A small molecule HIF-1α stabilizer that accelerates diabetic wound healing. Nature Communications 12:1.
Crossref
Crossref
Akira Mima. (2021) Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages. European Journal of Pharmacology 912, pages 174583.
Crossref
Crossref
Michaela A.A. Fuchs, Katharina A.E. Broeker, Julia Schrankl, Nicolai Burzlaff, Carsten Willam, Charlotte Wagner & Armin Kurtz. (2021) Inhibition of transforming growth factor β1 signaling in resident interstitial cells attenuates profibrotic gene expression and preserves erythropoietin production during experimental kidney fibrosis in mice. Kidney International 100:1, pages 122-137.
Crossref
Crossref
Monica Mazzarino, Ilaria Perretti, Carlotta Stacchini, Fabio Comunità, Xavier de la Torre & Francesco Botrè. (2021) UPLC–MS-Based Procedures to Detect Prolyl-Hydroxylase Inhibitors of HIF in Urine. Journal of Analytical Toxicology 45:2, pages 184-194.
Crossref
Crossref
Qiyan Zheng, Yahui Wang, Huisheng Yang, Luying Sun, Xinwen Fu, Ruojun Wei, Yu Ning Liu & Wei Jing Liu. (2021) Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology 11.
Crossref
Crossref
Yi Liu, Yu Lei, Sheng Guo & Zhili Zuo. (2020) Ensemble-based virtual screening in discovering potent inhibitors targeting Von Hippel-Lindau (VHL) E3 ubiquitin ligase. Life Sciences 262, pages 118495.
Crossref
Crossref
Marian Vincenzi, Flavia Anna Mercurio & Marilisa Leone. (2020) Protein Interaction Domains and Post-Translational Modifications: Structural Features and Drug Discovery Applications. Current Medicinal Chemistry 27:37, pages 6306-6355.
Crossref
Crossref
Zhan Yu, Zhihong Li, Quanwei Yu, Zhi Wang, Huilin Song, Hanyu Sun, Rufeng Fan, Angzhi Bi, Jun Zhang & Xiaojin Zhang. (2019) Discovery of prolyl hydroxylase 2 inhibitors with new chemical scaffolds as in vivo active erythropoietin inducers through a combined virtual screening strategy. Chemical Biology & Drug Design 95:2, pages 270-278.
Crossref
Crossref
Bijin Thajudeen, Sangeetha Murugapandian & Prabir Roy-Chaudhury. 2020. Chronic Renal Disease. Chronic Renal Disease
1189
1205
.
Tetsuya Kondo, Kenji Takeda, Ryo Muko, Akihiro Ito, Young-Chae Chang, Junji Magae & Takao Kataoka. (2019) 4-O-Methylascochlorin inhibits the prolyl hydroxylation of hypoxia-inducible factor-1α, which is attenuated by ascorbate. The Journal of Antibiotics 72:5, pages 271-281.
Crossref
Crossref
Mukul Jain, Amit Joharapurkar, Vishal Patel, Samadhan Kshirsagar, Brijesh Sutariya, Maulik Patel, Hiren Patel & Pankaj R. Patel. (2019) Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation. European Journal of Pharmacology 843, pages 113-120.
Crossref
Crossref
Hartmut Beck, Mario Jeske, Kai Thede, Friederike Stoll, Ingo Flamme, Metin Akbaba, Jens-Kerim Ergüden, Gunter Karig, Jörg Keldenich, Felix Oehme, Hans-Christian Militzer, Ingo V. Hartung & Uwe Thuss. (2018) Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia. ChemMedChem 13:10, pages 988-1003.
Crossref
Crossref
Lintao Jiang, Qinghao Guo, Shijiang Yang & Jun Cai. (2018) An electrochemical sensor based on a graphene/AuNP nanocomposite for the determination of prolyl hydroxylase. International Journal of Electrochemical Science 13:5, pages 4731-4740.
Crossref
Crossref
Yong Li, Yuan Chen, Yunxia Ma, Miljana Nenkov, Daniela Haase & Iver Petersen. (2018) Collagen prolyl hydroxylase 3 has a tumor suppressive activity in human lung cancer. Experimental Cell Research 363:1, pages 121-128.
Crossref
Crossref
Joshua Kaplan, Neeraj Sharma & Sean Dikdan. (2018) Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease. International Journal of Molecular Sciences 19:2, pages 389.
Crossref
Crossref
Pedro SoaresMorgan S. GaddJulianty FrostCarles GaldeanoLucy EllisOla EpemoluSonia RochaKevin D. ReadAlessio Ciulli. (2017)
Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase: Structure–Activity Relationships Leading to the Chemical Probe (2
S
,4
R
)-1-((
S
)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-
N
-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298)
. Journal of Medicinal Chemistry 61:2, pages 599-618.
Crossref
Crossref
Kevinkumar A. Kansagra, Deven Parmar, Rajendra H. Jani, Nuggehally R. Srinivas, Jason Lickliter, Harilal V. Patel, Devang P. Parikh, Heather Heading, Hardik B. Patel, Rahul J. Gupta, Chintan Y. Shah, Maulik R. Patel, Vyom N. Dholakia, Raghav Sukhadiya, Mukul R. Jain, Krupi V. Parmar & Kinjal Barot. (2017) Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers. Clinical Pharmacokinetics 57:1, pages 87-102.
Crossref
Crossref
Liyan Yue, Wei Wan, Pan Xu, Linjuan Li, Chen Wang, Yuanyuan Zhang, Heng Xu, Rukang Zhang, Junchi Hu, Wenchao Lu, Hao Jiang & Cheng Luo. 2018. Targeting Protein-Protein Interactions by Small Molecules. Targeting Protein-Protein Interactions by Small Molecules
179
211
.
Cormac T. Taylor & Sean P. Colgan. (2017) Regulation of immunity and inflammation by hypoxia in immunological niches. Nature Reviews Immunology 17:12, pages 774-785.
Crossref
Crossref
Naasson M. Mbenza, Praveen G. Vadakkedath, Duncan J. McGillivray & Ivanhoe K.H. Leung. (2017) NMR studies of the non-haem Fe(II) and 2-oxoglutarate-dependent oxygenases. Journal of Inorganic Biochemistry 177, pages 384-394.
Crossref
Crossref
Tessa Wilkin, Anna Baoutina & Natasha Hamilton. (2017) Equine performance genes and the future of doping in horseracing. Drug Testing and Analysis 9:9, pages 1456-1471.
Crossref
Crossref
Jing Pan, Yanmin Zhang, Ting Ran, Anyang Xu, Xin Qiao, Lingfeng Yin, Weineng Zhou, Lu Zhu, Junnan Zhao, Tao Lu, Yadong Chen & Yulei Jiang. (2017) QSAR modeling and in silico design of small-molecule inhibitors targeting the interaction between E3 ligase VHL and HIF-1
$$\alpha $$
α. Molecular Diversity 21:3, pages 719-739.
Crossref
Crossref
Teresa A.F. Cardote, Morgan S. Gadd & Alessio Ciulli. (2017) Crystal Structure of the Cul2-Rbx1-EloBC-VHL Ubiquitin Ligase Complex. Structure 25:6, pages 901-911.e3.
Crossref
Crossref
Anatole Besarab & Lynda Szczech. (2016) What are the Considerations in Balancing Benefits and Risks in Iron Treatment?. Seminars in Dialysis 30:1, pages 29-31.
Crossref
Crossref
John S. Debenham, Christina Madsen-Duggan, Matthew J. Clements, Thomas F. Walsh, Jeffrey T. Kuethe, Mikhail Reibarkh, Scott P. Salowe, Lisa M. Sonatore, Richard Hajdu, James A. Milligan, Denise M. Visco, Dan Zhou, Russell B. Lingham, Dominique Stickens, Julie A. DeMartino, Xinchun Tong, Michael Wolff, Jianmei Pang, Randy R. Miller, Edward C. Sherer & Jeffrey J. Hale. (2016)
Discovery of
N
-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia
. Journal of Medicinal Chemistry 59:24, pages 11039-11049.
Crossref
Crossref
Xin Xue, Ning-Yi Zhao, Hai-Tao Yu, Yuan Sun, Chen Kang, Qiong-Bin Huang, Hao-Peng Sun, Xiao-Long Wang & Nian-Guang Li. (2016)
Discovery of novel inhibitors disrupting HIF-1
?
/von Hippel?Lindau interaction through shape-based screening and cascade docking
. PeerJ 4, pages e2757.
Crossref
Crossref
Julianty Frost, Carles Galdeano, Pedro Soares, Morgan S. Gadd, Katarzyna M. Grzes, Lucy Ellis, Ola Epemolu, Satoko Shimamura, Marcus Bantscheff, Paola Grandi, Kevin D. Read, Doreen A. Cantrell, Sonia Rocha & Alessio Ciulli. (2016) Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition. Nature Communications 7:1.
Crossref
Crossref
Mario Thevis, Susan Milosovich, Hermes Licea-Perez, Dana Knecht, Tom Cavalier & Wilhelm Sch?nzer. (2016) Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls. Drug Testing and Analysis 8:8, pages 858-863.
Crossref
Crossref
Yonghua Lei, Tianhan Hu, Xingsen Wu, Yue Wu, Qichao Bao, Lianshan Zhang, Hua Xia, Haopeng Sun, Qidong You & Xiaojin Zhang. (2015) Affinity-Based Fluorescence Polarization Assay for High-Throughput Screening of Prolyl Hydroxylase 2 Inhibitors. ACS Medicinal Chemistry Letters 6:12, pages 1236-1240.
Crossref
Crossref
So Kim & Eun Yang. (2015) Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications. Molecules 20:11, pages 20551-20568.
Crossref
Crossref
Chris D Madsen, Jesper T Pedersen, Freja A Venning, Lukram Babloo Singh, Emad Moeendarbary, Guillaume Charras, Thomas R Cox, Erik Sahai & Janine T Erler. (2015)
Hypoxia and loss of
PHD
2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis
. EMBO reports 16:10, pages 1394-1408.
Crossref
Crossref
Sarah E. Wilkins, Emily Flashman, John S. Scotti, Richard J. Hopkinson, Rasheduzzaman Chowdhury & Christopher J. Schofield. 2015. 2-Oxoglutarate-Dependent Oxygenases. 2-Oxoglutarate-Dependent Oxygenases
169
209
.
Ann E. Lin, Federico C. Beasley, Joshua Olson, Nadia Keller, Robert A. Shalwitz, Thomas J. Hannan, Scott J. Hultgren & Victor Nizet. (2015) Role of Hypoxia Inducible Factor-1? (HIF-1?) in Innate Defense against Uropathogenic Escherichia coli Infection. PLOS Pathogens 11:4, pages e1004818.
Crossref
Crossref
Henry C. Nguyen, Haitao Yang, Jennifer L. Fribourgh, Leslie S. Wolfe & Yong Xiong. (2015) Insights into Cullin-RING E3 Ubiquitin Ligase Recruitment: Structure of the VHL-EloBC-Cul2 Complex. Structure 23:3, pages 441-449.
Crossref
Crossref
Prabir Roy-Chaudhury. 2015. Chronic Renal Disease. Chronic Renal Disease
771
780
.
O S Levchenkova & V E Novikov. (2014) INDUCERS OF THE REGULATORY FACTOR TO HYPOXIA ADAPTATION. I.P. Pavlov Russian Medical Biological Herald 22:2, pages 133-143.
Crossref
Crossref
Marc T. AbramsMartin KoserJulja BurchardWalter StrappsHuseyin MehmetMarian GindyDennis ZallerLaura Sepp-LorenzinoDominique Stickens. (2014) A Single Dose of EGLN1 siRNA Yields Increased Erythropoiesis in Nonhuman Primates. Nucleic Acid Therapeutics 24:6, pages 405-412.
Crossref
Crossref
Ingo Flamme, Felix Oehme, Peter Ellinghaus, Mario Jeske, J?rg Keldenich & Uwe Thuss. (2014) Mimicking Hypoxia to Treat Anemia: HIF-Stabilizer BAY 85-3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects. PLoS ONE 9:11, pages e111838.
Crossref
Crossref
Carles GaldeanoMorgan S. GaddPedro SoaresSalvatore ScaffidiInge Van MolleIpek BircedSarah HewittDavid M. DiasAlessio Ciulli. (2014) Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities. Journal of Medicinal Chemistry 57:20, pages 8657-8663.
Crossref
Crossref
Brendan M. Johnson, Brendt A. Stier & Stephen Caltabiano. (2014) Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863. Clinical Pharmacology in Drug Development 3:2, pages 109-117.
Crossref
Crossref
Michael H. Rabinowitz. (2013) Inhibition of Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Oxygen Sensors: Tricking the Body into Mounting Orchestrated Survival and Repair Responses. Journal of Medicinal Chemistry 56:23, pages 9369-9402.
Crossref
Crossref
Benedetta Bussolati, Carola Lauritano, Aldo Moggio, Federica Collino, Massimiliano Mazzone & Giovanni Camussi. (2013) Renal CD133+/CD73+ Progenitors Produce Erythropoietin under Hypoxia and Prolyl Hydroxylase Inhibition. Journal of the American Society of Nephrology 24:8, pages 1234-1241.
Crossref
Crossref
Dennis L. Buckley, Jeffrey L. Gustafson, Inge Van Molle, Anke G. Roth, Hyun Seop Tae, Peter C. Gareiss, William L. Jorgensen, Alessio Ciulli & Craig M. Crews. (2012) Small‐Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α. Angewandte Chemie International Edition 51:46, pages 11463-11467.
Crossref
Crossref
Dennis L. Buckley, Jeffrey L. Gustafson, Inge Van Molle, Anke G. Roth, Hyun Seop Tae, Peter C. Gareiss, William L. Jorgensen, Alessio Ciulli & Craig M. Crews. (2012) Niedermolekulare Inhibitoren der Wechselwirkung zwischen der E3‐Ligase VHL und HIF1α. Angewandte Chemie 124:46, pages 11630-11634.
Crossref
Crossref
Jeong-myung Ahn, Sun Jin You, Yun-Mi Lee, Se-Won Oh, Shin-young Ahn, Sejoong Kim, Ho Jun Chin, Dong-Wan Chae & Ki Young Na. (2012) Hypoxia-Inducible Factor Activation Protects the Kidney from Gentamicin-Induced Acute Injury. PLoS ONE 7:11, pages e48952.
Crossref
Crossref
Simon Beuck, Wilhelm Schänzer & Mario Thevis. (2012) Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis. Drug Testing and Analysis 4:11, pages 830-845.
Crossref
Crossref
Anu LaitalaEllinoora AroGail Walkinshaw, Joni M. MäkiMaarit RossiMinna HeikkiläEeva-Riitta Savolainen, Michael Arend, Kari I. KivirikkoPeppi KoivunenJohanna Myllyharju. (2012) Transmembrane prolyl 4-hydroxylase is a fourth prolyl 4-hydroxylase regulating EPO production and erythropoiesis. Blood 120:16, pages 3336-3344.
Crossref
Crossref
Petr Vachal, Shouwu Miao, Joan M. Pierce, Deodial Guiadeen, Vincent J. Colandrea, Matthew J. Wyvratt, Scott P. Salowe, Lisa M. Sonatore, James A. Milligan, Richard Hajdu, Anantha Gollapudi, Carol A. Keohane, Russell B. Lingham, Suzanne M. Mandala, Julie A. DeMartino, Xinchun Tong, Michael Wolff, Dietrich Steinhuebel, Gerard R. Kieczykowski, Fred J. Fleitz, Kevin Chapman, John Athanasopoulos, Gregory Adam, Can D. Akyuz, Dhirendra K. Jena, Jeffrey W. Lusen, Juncai Meng, Benjamin D. Stein, Lei Xia, Edward C. Sherer & Jeffrey J. Hale. (2012) 1,3,8-Triazaspiro[4.5]decane-2,4-diones as Efficacious Pan-Inhibitors of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia. Journal of Medicinal Chemistry 55:7, pages 2945-2959.
Crossref
Crossref
Dennis L. Buckley, Inge Van Molle, Peter C. Gareiss, Hyun Seop Tae, Julien Michel, Devin J. Noblin, William L. Jorgensen, Alessio Ciulli & Craig M. Crews. (2012) Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction. Journal of the American Chemical Society 134:10, pages 4465-4468.
Crossref
Crossref
Hirokazu Imai & Naoto Miura. (2011) 4) Hematological Disorders and Kidney Involvement.. Nihon Naika Gakkai Zasshi 100:9, pages 2552-2558.
Crossref
Crossref